NEWS
Jaguar Health Seeking Partner to Develop and Commercialize NP300 Second-Generation Antisecretory Prescription Drug Candidate for Treatment of General Diarrhea in DogsJaguar Health (NASDAQ:JAGX) is seeking a partner to develop and commercialize NP300, a second-generation antisecretory drug candidate for treating general diarrhea in dogs. NP300, derived from the Croton lechleri tree, has shown safety in dogs and shares similarities with Canalevia-CA1, the company's conditionally approved drug for chemotherapy-induced diarrhea. With approximately 6 million annual cases of acute and chronic diarrhea in dogs seen by U.S. veterinarians and no FDA-approved drugs for general canine diarrhea, the company aims to address this unmet need in the veterinary market.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
2681Followers
108Following
29KVisitors
Follow
103773561 : your company![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined")